Breakthrough COVID-19 in MS patients on DMTs

[agate]

An abstract from Multiple Sclerosis Journal (June 23, 2022)--"Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies":

Only registered and activated users can see links., Click Here To Register...

This is the conclusion they reached in the abstract:

The risk of breakthrough SARS-CoV-2 infections is higher in patients treated with ocrelizumab and fingolimod, and the rate of severe infections was significantly reduced in all the DMTs excluding ocrelizumab.

An article about this research appears in Multiple Sclerosis News Today (July 7), entitled "Higher COVID Risk Tied to 2 MS Therapies, Even with Vaccination":

Only registered and activated users can see links., Click Here To Register...